Clinics in Chest Medicine (CLIN CHEST MED)

Publisher: WB Saunders

Journal description

Each issue of Clinics in Chest Medicine reviews new diagnostic and management techniques for a single clinical problem--and makes them simple to apply. Its concise, comprehensive, and its editors and authors are respected experts.

Current impact factor: 2.17

Impact Factor Rankings

2015 Impact Factor Available summer 2015
2013 / 2014 Impact Factor 2.168
2012 Impact Factor 2.066
2011 Impact Factor 3.284
2010 Impact Factor 3.11
2009 Impact Factor 2.505
2008 Impact Factor 2.357
2007 Impact Factor 1.858
2006 Impact Factor 1.991
2005 Impact Factor 1.456
2004 Impact Factor 1.65
2003 Impact Factor 1.308
2002 Impact Factor 2.026
2001 Impact Factor 1.891
2000 Impact Factor 1.627
1999 Impact Factor 2.042
1998 Impact Factor 1.316
1997 Impact Factor 1.307
1996 Impact Factor 1.133
1995 Impact Factor 1.105
1994 Impact Factor 1.027
1993 Impact Factor 0.972
1992 Impact Factor 1.785

Impact factor over time

Impact factor
Year

Additional details

5-year impact 2.75
Cited half-life 7.80
Immediacy index 0.28
Eigenfactor 0.00
Article influence 0.93
Website Clinics in Chest Medicine website
Other titles Clinics in chest medicine
ISSN 0272-5231
OCLC 5433901
Material type Periodical, Internet resource
Document type Journal / Magazine / Newspaper, Internet Resource

Publisher details

WB Saunders

  • Pre-print
    • Author can archive a pre-print version
  • Post-print
    • Author can archive a post-print version
  • Conditions
    • Pre-print allowed on any website or open access repository
    • Voluntary deposit by author of authors post-print allowed on institutions open scholarly website including Institutional Repository, without embargo, where there is not a policy or mandate
    • Deposit due to Funding Body, Institutional and Governmental policy or mandate only allowed where separate agreement between repository and the publisher exists.
    • Permitted deposit due to Funding Body, Institutional and Governmental policy or mandate, may be required to comply with embargo periods of 12 months to 48 months .
    • Set statement to accompany deposit
    • Published source must be acknowledged
    • Must link to journal home page or articles' DOI
    • Publisher's version/PDF cannot be used
    • Articles in some journals can be made Open Access on payment of additional charge
    • NIH Authors articles will be submitted to PubMed Central after 12 months
    • Authors who are required to deposit in subject-based repositories may also use Sponsorship Option
    • 'WB Saunders' is an imprint of 'Elsevier'
  • Classification
    ​ green

Publications in this journal

  • Clinics in Chest Medicine 04/2015; DOI:10.1016/j.ccm.2015.02.004
  • Clinics in Chest Medicine 04/2015; DOI:10.1016/j.ccm.2015.02.002
  • Clinics in Chest Medicine 04/2015; DOI:10.1016/j.ccm.2015.02.003
  • Clinics in Chest Medicine 04/2015; DOI:10.1016/j.ccm.2015.02.010
  • Clinics in Chest Medicine 04/2015; DOI:10.1016/j.ccm.2015.02.006
  • Clinics in Chest Medicine 04/2015; DOI:10.1016/j.ccm.2015.02.009
  • [Show abstract] [Hide abstract]
    ABSTRACT: Diseases and therapies that reduce cell-mediated immunity increase the risk of nontuberculous mycobacterial (NTM) disease. Extrapulmonary NTM disease, including disseminated, skin, and catheter-related disease, is more common in immunosuppressed than immunocompetent patients. Mycobacterium avium complex remains the most common cause of NTM infection, but rapid growers including Mycobacterium abscessus, Mycobacterium chelonae, and Mycobacterium fortuitum play an important role in skin and catheter-related infections. With the exception of antibiotic prophylaxis for AIDS patients, the prevention of NTM remains difficult. Management is complicated, involving restoration of immune function and removal of catheters in addition to treatment with species-specific antibiotics per current guidelines. Copyright © 2015 Elsevier Inc. All rights reserved.
    Clinics in Chest Medicine 03/2015; 36(1):91-99. DOI:10.1016/j.ccm.2014.11.002
  • [Show abstract] [Hide abstract]
    ABSTRACT: Rapidly growing mycobacteria (RGM) include a diverse group of species. We address the treatment of the most commonly isolated RGM-M abscessus complex, M fortuitum, and M chelonae. The M abscessus complex is composed of 3 closely related species: M abscessus senso stricto (hereafter M abscessus), M massiliense, and M bolletii. Most studies address treatment of M abscessus complex, which accounts for 80% of lung disease caused by RGM and is the second most common RGM to cause extrapulmonary disease (after M fortuitum). The M abscessus complex represent the most drug-resistant nontuberculous mycobacteria and are the most difficult to treat. Copyright © 2015 Elsevier Inc. All rights reserved.
    Clinics in Chest Medicine 03/2015; 36(1):67-78. DOI:10.1016/j.ccm.2014.10.004
  • [Show abstract] [Hide abstract]
    ABSTRACT: The incidence of pulmonary nontuberculous mycobacterial disease is increasing. Despite aggressive medical therapy, a subset of patients will experience treatment failure or suffer disabling or life-threatening symptoms. The use of anatomic lung resection in addition to optimal medical management may, in select cases, result in improved clinical outcomes. More data are needed to confirm this approach. For those with nontuberculous mycobacterial infection, treatment in a multidisciplinary setting including surgeons familiar with operative techniques specific to infectious lung disease will improve patient care. Copyright © 2015 Elsevier Inc. All rights reserved.
    Clinics in Chest Medicine 03/2015; 36(1):117-122. DOI:10.1016/j.ccm.2014.11.004
  • [Show abstract] [Hide abstract]
    ABSTRACT: Nontuberculous mycobacteria (NTM) are important emerging cystic fibrosis (CF) pathogens. Factors including the steady aging of the CF population, the apparent increase of NTM in the environment, and the potential for patient-to-patient transmission, may contribute to increased acquisition. Diagnosis of NTM disease is challenging due to disease overlap; thus, comprehensive care of the CF patient must be optimized to assess the clinical impact of the NTM (indolent versus active), and to improve response to treatment. The development of a CF-specific approach to the diagnosis and treatment of NTM infection is a research priority for the CF community. Copyright © 2015 Elsevier Inc. All rights reserved.
    Clinics in Chest Medicine 03/2015; 36(1):101-115. DOI:10.1016/j.ccm.2014.11.003
  • [Show abstract] [Hide abstract]
    ABSTRACT: This article discusses obesity, its contribution to clinical outcomes, and the current literature on nutrition. More than one third of Americans are obese. Literature suggests that, among critically ill patients, the relationship between obesity and outcomes is complex. Obese patients may be at greater risk of developing acute respiratory distress syndrome (ARDS) than normal weight patients. Although obesity may confer greater morbidity in intensive care, it seems to decrease mortality. ARDS is a catabolic state; patients demonstrate a profound inflammatory response, multiple organ dysfunction, and hypermetabolism, often with malnutrition. The concept of pharmaconutrition has emerged. Copyright © 2014 Elsevier Inc. All rights reserved.
    Clinics in Chest Medicine 12/2014; DOI:10.1016/j.ccm.2014.08.005
  • [Show abstract] [Hide abstract]
    ABSTRACT: Given the high incidence and mortality of acute respiratory distress syndrome (ARDS) in critically ill patients, every practitioner needs a bedside approach both for early identification of patients at risk for ARDS and for the appropriate evaluation of patients who meet the diagnostic criteria of ARDS. Recent advances such as the Lung Injury Prediction score, the Early Acute Lung Injury score, and validation of the SpO2/Fio2 ratio for assessing the degree of hypoxemia are all practical tools to aid the practitioner in caring for patients at risk of ARDS. Copyright © 2014 Elsevier Inc. All rights reserved.
    Clinics in Chest Medicine 12/2014; DOI:10.1016/j.ccm.2014.08.007
  • [Show abstract] [Hide abstract]
    ABSTRACT: Regenerative medicine has entered a rapid phase of discovery, and much has been learned in recent years about the lung's response to injury. This article first summarizes the cellular and molecular mechanisms that damage the alveolar-capillary barrier, producing acute respiratory distress syndrome (ARDS). The latest understanding of endogenous repair processes is discussed, highlighting the diversity of lung epithelial progenitor cell populations and their regulation in health and disease. Finally, the past, present, and future of exogenous cell-based therapies for ARDS is reviewed. Copyright © 2014 Elsevier Inc. All rights reserved.
    Clinics in Chest Medicine 12/2014; DOI:10.1016/j.ccm.2014.08.015
  • [Show abstract] [Hide abstract]
    ABSTRACT: Our ability to define appropriate molecular targets for preclinical development and develop better methods needs to be improved, to determine the clinical value of novel acute respiratory distress syndrome (ARDS) agents. Clinical trials must have realistic sample sizes and meaningful end points and use the available observation and meta-analytical data to inform design. Biomarker-driven studies or defined ARDS subsets should be considered to categorize specific at-risk populations most likely to benefit from a new treatment. Innovations in clinical trial design should be pursued to improve the outlook for future interventional trials in ARDS. Copyright © 2014 Elsevier Inc. All rights reserved.
    Clinics in Chest Medicine 12/2014; DOI:10.1016/j.ccm.2014.08.009
  • [Show abstract] [Hide abstract]
    ABSTRACT: Immunosuppression predisposes the host to development of pulmonary infections, which can lead to respiratory failure and the development of acute respiratory distress syndrome (ARDS). There are multiple mechanisms by which a host can be immunosuppressed and each is associated with specific infectious pathogens. Early invasive diagnostic modalities such as fiber-optic bronchoscopy with bronchoalveolar lavage, transbronchial biopsy, and open lung biopsy are complementary to serologic and noninvasive studies and assist in rapidly establishing an accurate diagnosis, which allows initiation of appropriate therapy and may improve outcomes with relative safety. Copyright © 2014 Elsevier Inc. All rights reserved.
    Clinics in Chest Medicine 12/2014; DOI:10.1016/j.ccm.2014.08.008
  • [Show abstract] [Hide abstract]
    ABSTRACT: The development and severity of acute respiratory distress syndrome (ARDS) are closely related to dysregulated inflammation, and the duration of ARDS and eventual outcomes are related to persistent inflammation and abnormal fibroproliferation. Corticosteroids are potent modulators of inflammation and inhibitors of fibrosis that have been used since the first description of ARDS in attempts to improve outcomes. There is no evidence that corticosteroids prevent the development of ARDS among patients at risk. High-dose and short-course treatment with steroids does not improve the outcomes of patients with ARDS. Additional studies are needed to recommend treatment with steroids for ARDS. Copyright © 2014 Elsevier Inc. All rights reserved.
    Clinics in Chest Medicine 12/2014; DOI:10.1016/j.ccm.2014.08.014
  • [Show abstract] [Hide abstract]
    ABSTRACT: This article reviews the evolving definitions and epidemiology of the acute respiratory distress syndrome (ARDS) and highlights current efforts to improve identification of high-risk patients, thus to target prevention and early treatment before progression to ARDS. This information will be important for general practitioners and intensivists interested in improving the care of patients at risk for ARDS, and clinical researchers interested in designing clinical trials targeting the prevention and early treatment of acute lung injury. Copyright © 2014 Elsevier Inc. All rights reserved.
    Clinics in Chest Medicine 12/2014; DOI:10.1016/j.ccm.2014.08.002